Cusatuzumab is a Monoclonal Antibody owned by Argenx, and is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing.
Cusatuzumab (ARGX-110) acts as CD70 antigen inhibitor. It blocks tumor growth, blocks immune escape and kills CD70+ tumor cells. It selectively inhibits CD70, the ligand of CD27, as well as depletes CD70 over-expressing cells. In normal tissues, expression of CD70 is transient and restricted to activated B and T cells and mature dendritic cells. The CD70/CD27 axis has gained increasing interest among the immunologists, because of its capacity to regulate immunity versus tolerance.
The revenue for Cusatuzumab is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cusatuzumab NPV Report.
Cusatuzumab is originated and owned by Argenx.
Cusatuzumab (ARGX-110) is under development for the treatment of solid tumors, such as renal cell carcinoma, acute promyelocytic leukemia, platinum-refractory ovarian cancer, head and neck cancer, nasopharyngeal carcinoma, myoepithelial carcinoma, mesothelioma and hematological malignancies including refractory Waldenstrom’s macroglobulinemia (WM), relapsed/refractory T-cell lymphomas such as Sezary syndrome (cutaneous T-cell lymphoma), angioimmunoblastic T-cell lymphoma (AITL), acute myeloid leukemia(AML) and high risk myelodysplatic syndrome. The therapeutic candidate is administered through intravenous or subcutaneous route. It is a glyco-engineered fully human antibody developed based on SIMPLE antibody platform. ARGX-110 is equipped with Potelligent to enhance its ability to destroy CD70-positive tumor cells. The drug candidate was also under development for chronic myelocytic leukemia (CML), inflammatory and autoimmune disorders.
Argenx is an immunology company that focuses on the development of human antibodies. The company is primarily developing products for autoimmune diseases. Its key product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults which are anti-acetylcholine receptor (AChR) antibody positive. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118, ARGX-119 and ARGX-120. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as Nhance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenx is headquartered in Breda, the Netherlands.
The company reported revenues of (US Dollars) US$497.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$41.2 million in FY2020. The operating loss of the company was US$348.8 million in FY2021, compared to an operating loss of US$477.6 million in FY2020. The net loss of the company was US$408.3 million in FY2021, compared to a net loss of US$608.5 million in FY2020. The company reported revenues of US$138 million for the third quarter ended September 2022, an increase of 39.9% over the previous quarter.
Quick View – Cusatuzumab
|Highest Development Stage|